Literature DB >> 26250118

Evaluation of rheumatoid factor and anti-citrullinated peptide antibodies in relation to rheumatological manifestations in patients with leprosy from Southern Brazil.

Carla Fontoura Dionello1, Shirley Ramos Rosa Utiyama1, Sebastião Cézar Radominski2, Ewalda Stahlke3, Servio Tulio Stinghen1, Iara Jose de Messias-Reason4.   

Abstract

BACKGROUND: Leprosy patients may present several osteoarticular complaints, which require further evaluation of inflammatory diseases, such as rheumatoid arthritis (RA). Therefore, an adequate clinical assessment in addition to testing for rheumatoid factors (RF) and anticyclic citrullinated peptide antibodies (anti-CCP), can be useful in order to establish the correct diagnosis.
METHOD: In this study, the relation of RF and anti-CCP with rheumatological manifestations was evaluated in 97 leprosy patients from Southern Brazil. The results were compared to RA patients and healthy controls from the same geographical area and ethnic background.
RESULTS: Neuropathy was observed in 71.1% and arthritis in 35.1% of the leprosy patients. A high frequency of RF positivity was observed among the leprosy patients (41.2%, 40/97), with RF immunoglobulin A (IgA) significantly associated with arthritis (OR = 7.9, 95% CI = 1.5-40.6 P = 0.008). Anti-CCP was observed in 9.3% (9/97) of the patients, with anti-CCP2 being the most frequent subtype. Only 4.1% (4/97) of the patients were RF and anti-CCP concomitantly positive. RF IgM showed a significant association with leprosy when compared to healthy controls (P < 0.0001) whereas for anti-CCP2 no significant results were observed (P = 0.0585). However, both biomarkers showed a strong association with RA when compared to leprosy in patients from the same geographical area and ethnic background (anti-CCP2 OR = 38.6; 95% CI = 16.49-90.26; P < 0.0001 and RF IgM OR = 4.51; 95% CI = 2.62-7.77; P < 0.0001).
CONCLUSION: Due to the similarity of some rheumatological manifestations in leprosy with other inflammatory diseases, such as RA, clinical and laboratorial evaluation of affected patients must be carefully assessed in order to achieve proper diagnosis and treatment.
© 2015 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  anti-CCP antibodies; leprosy; rheumatoid arthritis; rheumatoid factor; rheumatological manifestations

Mesh:

Substances:

Year:  2015        PMID: 26250118     DOI: 10.1111/1756-185X.12668

Source DB:  PubMed          Journal:  Int J Rheum Dis        ISSN: 1756-1841            Impact factor:   2.454


  2 in total

Review 1.  New therapeutic patents used for the treatment of leprosy: a review.

Authors:  Nayara Gomes Lima Santos; Karen Perez Pereira Ramos; Saravanan Shanmugam; Fernanda Oliveira de Carvalho; Luciana Garcez Barreto Teixeira; Érika Ramos Silva; Juliana de Vasconcelos Cerqueira-Braz; Paula Santos Nunes; Adriano Antunes de Souza Araújo
Journal:  Epidemiol Infect       Date:  2018-08-07       Impact factor: 4.434

2.  Rheumatoid arthritis-like features in Hansen disease: A case report.

Authors:  Le-Nyu Gao; Bing Zhong; Yong Wang
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.